Advertisement

Organisation › Details
Boehringer Ingelheim Venture Fund (BIVF)
Created in 2010, the Boehringer Ingelheim Venture Fund GmbH (BIVF) invests in groundbreaking therapeutics-focused biotechnology companies to drive innovation in biomedical research. BIVF is searching for significant enhancements in patient care through pioneering science and its clinical translation by building long-term relationships with scientists and entrepreneurs. BIVF’s focus is to target unprecedented therapeutic concepts addressing high medical needs in immuno-oncology, in regenerative medicine or infectious diseases. These may include novel platform technologies to address so far undruggable targets, new generation vaccines and/or new biological entities, such as oncolytic virotherapy as well as Digital Health. BIVF takes an active role within its portfolio companies – delivering significant added value through its own extensive drug discovery, scientific and managerial expertise. BIVF has € 300 million under management and currently supervises a portfolio of 29 companies. *
![]() |
Start | 2010-03-01 established |
![]() |
Industry | venture capital |
Industry 2 | pharmaceutical | |
![]() |
Person | Kalkbrenner, Frank (Boehringer 201308 CVP + Head of BIVF + CEO Acousia Therapeutics GmbH) |
![]() |
Region | Ingelheim |
Country | Germany | |
Street | 173 Binger Str. | |
City | 55216 Ingelheim | |
Tel | +49-6132-77-8740 | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | n. a. |
Currency | EUR | |
Annual sales | 300,000,000 (capital under management (2020) 2020-07-21) | |
* Document for �About Section�: Quantro Therapeutics GmbH. (7/21/20). "Press Release: Quantro Therapeutics Launched with Breakthrough Oncology Drug Discovery Platform". Vienna. | ||
Record changed: 2021-02-21 |
Advertisement

More documents for Boehringer Ingelheim Venture Fund (BIVF)
- [1] Libra Therapeutics, Inc.. (9/23/20). "Press Release: Libra Launches with $29M Series A to Develop Novel Therapeutics for Neurodegenerative Diseases". San Diego, CA....
- [2] T3 Pharmaceuticals AG. (7/22/20). "Press Release: T3 Pharma Raises 25M CHF to Advance Bacterial Cancer Therapy through Clinic". Basel....
- [3] Quantro Therapeutics GmbH. (7/21/20). "Press Release: Quantro Therapeutics Launched with Breakthrough Oncology Drug Discovery Platform". Vienna....
- [4] Boehringer Ingelheim. (7/2/20). "Press Release: Boehringer Ingelheim Launches External Innovation Hub in China". Ingelheim....
- [5] DiogenX. (6/16/20). "Press Release: DiogenX Raises €4.5M in Seed Financing from Advent France Biotechnology, Boehringer Ingelheim Venture Fund and JDRF T1D Fund". Marseille....
- [6] eTheRNA Immunotherapeutics N.V.. (6/16/20). "Press Release: eTheRNA Raises EUR 34 Million in Series B Financing to Accelerate Multiple mRNA Therapeutic Development Programs Through to Clinical Proof of Concept". Niel....
- [7] Rgenta Therapeutics, Inc.. (4/2/20). "Press Release: Rgenta Therapeutics Launches with $20 Million Seed Investment". Cambridge, MA....
- [8] HepaRegenix GmbH. (1/21/20). "Press Release: HepaRegenix GmbH Secures Series B Financing in Excess of €11 Mio. to Advance First Drug Candidate to the Clinic". Tübingen....
- [9] NBE Therapeutics AG. (1/10/20). "Press Release: NBE-Therapeutics Closes a USD 22M Series C Financing Round". Basel....
- [10] Eyevensys S.A.S.. (1/8/20). "Press Release: Eyevensys Closes $30M Series B Financing". Paris & Fort Worth, TX....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Advertisement

» top